Our goal is to do the testing in a manner that helps the physician catch things before they fully develop, which will help us deliver quality of life and potentially save lives along the way

On the backdrop of the pandemic, PMLS has been proactive in combating the spread of the virus by regularly ramping up their testing capacity while also acing the challenges on the way. One of the biggest problems out there right now is getting supplies. Labs in general that are focused on just laboratory services don’t have efficient supply chains that they can utilize or tap into. On the contrary, PMLS has its own supply chain formed out of the coordination with its sister companies who develop their own transport media and collection kits. That, in turn, has helped them in handling large volumes of samples daily. “Currently we have the capability to test 50,000 samples a day. We are now in the process of validating added machinery, as soon as they arrive, we would be able to hit the mark of testing 100,000 samples a day,” avidly affirms Michael Conroy, project manager and VP of Compliance at PMLS. He also elucidates that, “We are doing extensive research on our next gen sequence scene around the Covid-19 virus. We are mapping the genome and storing that data to get it out in the right hands, while also using our scientists and R&D team to look at different methods of sample collection and find as many ways possible to collect the sample.”

Alongside, PMLS is continually developing its HeartPro panel, which aims to replace the 40-year-old lipid panel with advanced lipid testing. By focusing on the Genetic Pro panel and cancer testing, they deliver quality test information that can help physicians change the treatment plan to prevent the patients from developing the disease. “Our goal is to do the testing in a manner that helps the physician catch things before they fully develop, which will help us deliver quality of life and potentially save lives along the way,” concludes Tom on a hopeful note.